News About: Pharm. Industry
Boryung Attains Manufacturing Capability for Antibiotics with Global Standards
Boryung Pharmaceutical Co. Ltd. held a ceremony last week for the completion of Ansan manufacturing plant expansion, where an independent production capability for the company's cephalosporin family of antibiotic prod...
Handok-Aventis Introduces Once-Daily Basal Insulin Treatment
Handok-Aventis Pharma announced that the company is to launch Lantus (insulin glargine [rDNA origin] injection) for the treatment of type 1 and type 2 diabetes in the domestic market starting March 29th.
Lantus is ...
Dong Sung to Export Cosmetic Products to Taiwan
Dong Sung Corporation (President: Lee Yang-koo) signed a multi-year export agreement with Meiyuhshin International Co. of Taiwan on March 23rd for the supply of various skin care products manufactured by Lykea Cosmeti...
Alleged Discovery of Contamination Found in Tylenol ER Tablets
According to the retail pharmacy community, a large amount of defective Tylenol ER (extended release) tablets, marketed by Janssen Korea, is currently being distributed and supplied to the retail pharmacies.
Based ...
Examples on Specific Insurance Claims by Medical Institutions Now Available
The Health Insurance Review Agency (HIRA) recently announced a provision of the summarized review results on the actual insurance claims submitted for the specific instances of riluzole, antithrombin III and human imm...
Hanmi Vows Not to Supply Amodipine at Significantly Low Price Level
In response to the outcome from the open competitive tendering for the Veterans Hospital Network, where the winning bid for Hanmi Pharmaceutical's Amodipine was significantly below the general market price level, the ...
Dong-A Receives US FDA Approval on Phase II Clinical Trial for DA-8159
Dong-A Pharmaceutical said its novel medication for male erectile dysfunction (ED) treatment, under a codename DA-8159, has received an approval for Phase II clinical trial by the United States Food and Drug Administr...
Boryung Announced Year 2004 Financial Results
Boryung Pharmaceutical announced of its Year 2004 financial performance results, in which the company recorded the total revenue of 22.5 billion won, up 11.22% from the prior fiscal period.
The company's operating ...
Proposed Availability of Lower-Dose Psychotropic Drugs Rejected
In response to the request made by the Seoul Pharmaceutical Association (SPA) on the proposed availability of psychotropic drugs in smaller dosage units, Roche Korea and Myungin Pharm both stated that they are unable ...
Price Deterioration Evidenced in Successful Drug Bids
The result from an open competitive tender by the Veterans Hospital Network indicates that there is a continuous deterioration in the successful drug bid prices, which could potentially jeopardize the adequate stream ...
